Načítá se...
Adverse Effects of GLP-1 Receptor Agonists
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic drugs that improve glycemic control and many other atherosclerosis-related parameters in patients with type 2 diabetes (T2D). However, the use of this relatively new class of drugs may be associated with certain...
Uloženo v:
| Vydáno v: | Rev Diabet Stud |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SBDR - Society for Biomedical Diabetes Research
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5397288/ https://ncbi.nlm.nih.gov/pubmed/26177483 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1900/RDS.2014.11.202 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|